Open AccessCase Report and Review of Literature: Camrelizumab Combined with Fuzuloparib and Apatinib for Platinum-Resistant Recurrent Ovarian Cancer
Author(s) -
Yingliang Wu,
Xiaoyan Zhang,
Lian Li,
Wei Yang,
Yan Zhang,
Chenglei Gu,
Zhe Zhang,
Jiahuan Zhou,
Lulu Liu,
Mingxia Ye,
Yuanguang Meng
Publication year - 2022
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s375643
Subject(s) - apatinib , medicine , chemotherapy , oncology , complete response , ovarian cancer , adverse effect , progression free survival , bevacizumab , cancer , surgery , gynecology